Altamira Therapeutics Ltd (CYTO) concluded trading on 11/15/23 at a closing price of $0.10, with 6.65 million shares of worth about $0.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -88.62% during that period and on Wednesday the price saw a loss of about -1.00%. Currently the company’s common shares owned by public are about 8.83M shares, out of which, 8.78M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the CYTO stock and their offered price forecasts bring an average price target of $286.10. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $286.10 and could fall to a lowest price of $286.10. The stock’s current price level is 99.97% above of average price target set by the analysts, while a rise to estimated low would result in gain of 99.97% for the stock. However, touching the estimated high of $286.10 would mean a gain of 99.97% for the stock.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altamira Therapeutics Ltd (NASDAQ: CYTO) started trading at $0.11, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.1114, or with a loss of -1.00%. Stock saw a price change of -15.09% in past 5 days and over the past one month there was a price change of -47.56%. Year-to-date (YTD), CYTO shares are showing a performance of -97.96% which decreased to -98.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.09 but also hit the highest price of $6.31 during that period. The average intraday trading volume for Altamira Therapeutics Ltd shares is 969.70K. The stock is currently trading -31.70% below its 20-day simple moving average (SMA20), while that difference is down -53.23% for SMA50 and it goes to -88.89% lower than SMA200.
Altamira Therapeutics Ltd (NASDAQ: CYTO) currently have 8.83M outstanding shares and institutions hold larger chunk of about 10.07% of that.
The stock has a current market capitalization of $0.87M and its 3Y-monthly beta is at 1.64. It has Quick Ratio of 0.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CYTO, volatility over the week remained 15.57% while standing at 14.74% over the month.
Analysts are in expectations that Altamira Therapeutics Ltd (CYTO) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same.
Analysts at 1 brokerage firms have issued recommendations for the Altamira Therapeutics Ltd (CYTO)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
